The signaling pathways implicated in impairment of hepatic autophagy in glycogen storage disease type Ia

被引:19
|
作者
Gautam, Sudeep [1 ]
Zhang, Lisa [1 ]
Arnaoutova, Irina [1 ]
Lee, Cheol [1 ]
Mansfield, Brian C. [1 ,2 ]
Chou, Janice Y. [1 ]
机构
[1] Eunice Kennedy Shriver Natl Inst Child Hlth & Hum, Div Translat Med, Sect Cellular Differentiat, Columbia, MD 21046 USA
[2] Fdn Fighting Blindness, Columbia, MD 21046 USA
基金
美国国家卫生研究院;
关键词
MAMMALIAN TARGET; RAPAMYCIN MTOR; SIRT1; METABOLISM; PHOSPHORYLATION; AMPK; MODULATION; COMPLEX; ALPHA; LIVER;
D O I
10.1093/hmg/ddaa007
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Glucose-6-phosphatase-alpha (G6Pase-alpha or G6PC) deficiency in glycogen storage disease type-Ia (GSD-Ia) leads to impaired hepatic autophagy, a recycling process important for cellular metabolism and homeostasis. Autophagy can be regulated by several energy sensing pathways, including sirtuin 1 (SIRT1), forkhead box O (FoxO), AMP-activated protein kinase (AMPK), peroxisome proliferator-activated receptor-alpha (PPAR-alpha), and mammalian target of rapamycin (mTOR). Using 10-day old global G6pc-deficient (G6pc-/-) mice, hepatic autophagy impairment was attributed to activation of mTOR and inhibition of AMPK signaling. In other studies, using adult liver-specific G6pc-deficient mice at both pre-tumor and tumor stages, hepatic autophagy impairment was attributed to downregulation of SIRT1 signaling and mTOR was not implicated. In this study, we provide a detailed analysis of the major autophagy pathways in young G6pc-/- mice over the first 4 weeks of life. We show that impaired SIRT1, FoxO3a, AMPK, and PPAR-alpha signaling are responsible for autophagy impairment but mTOR is involved minimally. Hepatic SIRT1 overexpression corrects defective autophagy, restores the expression of FoxO3a and liver kinase B1 but fails to normalize impaired PPAR-alpha expression or metabolic abnormalities associated with GSD-Ia. Importantly, restoration of hepatic G6Pase-alpha expression in G6pc-/- mice corrects defective autophagy, restores SIRT1/FoxO3a/AMPK/PPAR-alpha signaling and rectifies metabolic abnormalities. Taken together, these data show that hepatic autophagy impairment in GSD-Ia is mediated by downregulation of SIRT1/FoxO3a/AMPK/PPAR-alpha signaling.
引用
收藏
页码:834 / 844
页数:11
相关论文
共 50 条
  • [1] Downregulation of SIRT1 signaling underlies hepatic autophagy impairment in glycogen storage disease type Ia
    Cho, Jun-Ho
    Kim, Goo-Young
    Pan, Chi-Jiunn
    Anduaga, Javier
    Choi, Eui-Ju
    Mansfield, Brian C.
    Chou, Janice Y.
    PLOS GENETICS, 2017, 13 (05):
  • [2] Hepatic Adenomas in Type Ia Glycogen Storage Disease
    不详
    GASTROENTEROLOGY, 2008, 135 (06) : 1817 - 1818
  • [3] Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia
    Waskowicz, Lauren R.
    Zhou, Jin
    Landau, Dustin J.
    Brooks, Elizabeth D.
    Lim, Andrea
    Yavarow, Zollie A.
    Kudo, Tsubasa
    Zhang, Haoyue
    Wu, Yajun
    Grant, Stuart
    Young, Sarah P.
    Huat, Bay Boon
    Yen, Paul M.
    Koeberl, Dwight D.
    HUMAN MOLECULAR GENETICS, 2019, 28 (01) : 143 - 154
  • [4] Neutrophilia and elevated serum cytokines are implicated in glycogen storage disease type Ia
    Kim, So Youn
    Chen, Li-Yuan
    Yiu, Wal Han
    Weinstein, David A.
    Chou, Janice Y.
    FEBS LETTERS, 2007, 581 (20) : 3833 - 3838
  • [5] Emerging roles of autophagy in hepatic tumorigenesis and therapeutic strategies in glycogen storage disease type Ia: A review
    Cho, Jun-Ho
    Weinstein, David A.
    Lee, Young Mok
    JOURNAL OF INHERITED METABOLIC DISEASE, 2021, 44 (01) : 118 - 128
  • [6] HEPATIC ADENOMATA IN TYPE-IA GLYCOGEN-STORAGE-DISEASE
    COIRE, CI
    QIZILBASH, AH
    CASTELLI, MF
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 1987, 111 (02) : 166 - 169
  • [7] Downregulation of pathways implicated in liver inflammation and tumorigenesis of glycogen storage disease type Ia mice receiving gene therapy
    Kim, Goo-Young
    Kwon, Joon Hyun
    Cho, Jun-Ho
    Zhang, Lisa
    Mansfield, Brian C.
    Chou, Janice Y.
    HUMAN MOLECULAR GENETICS, 2017, 26 (10) : 1890 - 1899
  • [8] Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia
    Yavarow, Zollie A.
    Kang, Hye-Ri
    Waskowicz, Lauren R.
    Bay, Boon-Huat
    Young, Sarah P.
    Yen, Paul M.
    Koeberl, Dwight D.
    HUMAN MOLECULAR GENETICS, 2020, 29 (02) : 286 - 294
  • [9] Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa)
    Benjamin L. Farah
    Rohit A. Sinha
    Yajun Wu
    Brijesh K. Singh
    Andrea Lim
    Masahiro Hirayama
    Dustin J. Landau
    Boon Huat Bay
    Dwight D. Koeberl
    Paul M. Yen
    Scientific Reports, 7
  • [10] Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa)
    Farah, Benjamin L.
    Sinha, Rohit A.
    Wu, Yajun
    Singh, Brijesh K.
    Lim, Andrea
    Hirayama, Masahiro
    Landau, Dustin J.
    Bay, Boon Huat
    Koeberl, Dwight D.
    Yen, Paul M.
    SCIENTIFIC REPORTS, 2017, 7